A Potential New Target for ALS Therapies
The Context: Mutations in a gene called NEK1 are known to cause ALS in a subset of patients, but how exactly these mutations affect motor neurons...
News
The latest news and updates about NYSCF and our collaborators
18 Results
Clear Filters
Finding ALS Treatments That Work For All Patients
The Context: ALS is a disease that manifests differently in each patient, with some cases resulting from genetic predispositions, and others sporadically. Because the causes can...
How ‘Dancing Molecules’ Can Improve the Way We Study Neurodegenerative Disease
The Context: Turning patient stem cells into the different cell types of the brain offers immense promise for studying and treating neurodegenerative diseases such as Alzheimer’s,...
What are Stem Cells, and How Can They Accelerate Better Treatments for Disease?
Alzheimer’s, Parkinson’s, multiple sclerosis, cancer: they’re all diseases that are, to this day, largely a mystery, and treatment options are scarce. But thanks to stem cells,...
Creating a Human Nerve Circuit in a Dish to Study Movement Disorders
The Context: Neuromuscular disorders such as ALS arise from degeneration of brain cells that send signals to the muscles, and there are no treatments that address...
Promising Results Published on a New ALS Drug Discovered with NYSCF Support
Ezogabine (an epilepsy drug), has successfully reduced a hallmark of ALS in 65 patients participating in a phase 2 clinical trial, according to a recent report...
A New Therapeutic Angle for ALS
The Context: Amyotrophic lateral sclerosis (ALS) affects motor neurons, the cells that send signals to our muscles, gradually paralyzing patients. Scientists know that a mutation in...
NYSCF-Supported Research Leads to Successful Phase 2 Clinical Trial for ALS
An epilepsy drug, initially tested using a stem cell model of ALS developed with NYSCF support, has successfully reduced motor neuron excitability (a hallmark of the...
Biotech Company Founded By Dr. Justin Ichida Receives Fast-Track Grant
The National Institute of Neurological Disorders and Stroke (NINDS) have awarded a 3.7 million dollar Small Business Innovation Research (SBIR) Fast-Track grant to a biotech company...
Four NYSCF Innovators Featured In Nature Article on Embryonic Stem Cell Research
Over the past 20 years, embryonic stem cell (ESC) research has evolved from a brand new field with lots of promise to one that is actively...
NYSCF Innovator Discovers Mechanism Leading to Toxic Buildup in ALS and Frontotemporal Dementia
New research from the lab of NYSCF — Robertson Investigator Justin Ichida, PhD, at the University of Southern California suggests that a faulty gene can cause...
Announcing The 2017 Class of NYSCF – Robertson Investigators
NYSCF welcomed six of the most talented stem cell researchers and neuroscientists from around the world into the NYSCF Investigator Program and the NYSCF Innovator Community....
NYSCF Research Institute Teams Up With National Stem Cell Foundation to Advance Neurodegeneration Research
The National Stem Cell Foundation (NSCF) and the NYSCF Research Institute announced that a grant from NSCF will be used to fund NYSCF research on cell...
NYSCF Research Institute and Yumanity Therapeutics Announce Discovery Collaboration
The NYSCF Research Institute announced a new collaboration with Yumanity Therapeutics, a company focused on transforming drug discovery for diseases caused by protein misfiling, to generate...
Stem Cell Treatments
NYSCF does not treat patients with stem cell therapies. Please visit www.clinicaltrials.gov for a complete listing of clinical trials being conducted worldwide, or consult your physician. Stem cell research...
NYSCF Congratulates Dr. Lorenz Studer on Being Named a 2015 MacArthur Fellow
The MacArthur Foundation named Dr. Lorenz Studer a 2015 MacArthur Fellow. A Founding member of NYSCF’s Medical Advisory Board, Dr. Studer served on inaugural juries of...
NYSCF-Supported ALS Research Identifies Promising New Biological Pathway
Researchers at the Harvard Stem Cell Institute, led by NYSCF Chief Scientific Officer Dr. Kevin Eggan, discovered a new, promising treatment for ALS, or Lou Gehrig’s...
NYSCF – Robertson Investigator Discovers First Ever Selector Gene for Neurons
NYSCF – Robertson Stem Cell Investigator Dr. Paola Arlotta, of Harvard University, published her latest work on gene co-regulation in Nature Neuroscience. The regulatory logic, or...